MX2022001403A - Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. - Google Patents
Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.Info
- Publication number
- MX2022001403A MX2022001403A MX2022001403A MX2022001403A MX2022001403A MX 2022001403 A MX2022001403 A MX 2022001403A MX 2022001403 A MX2022001403 A MX 2022001403A MX 2022001403 A MX2022001403 A MX 2022001403A MX 2022001403 A MX2022001403 A MX 2022001403A
- Authority
- MX
- Mexico
- Prior art keywords
- siglec
- corticosteroids
- antibodies
- methods
- administering anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882330P | 2019-08-02 | 2019-08-02 | |
| PCT/US2020/044583 WO2021026021A1 (en) | 2019-08-02 | 2020-07-31 | Methods of administering anti-siglec-8 antibodies and corticosteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001403A true MX2022001403A (es) | 2022-03-25 |
Family
ID=74504001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001403A MX2022001403A (es) | 2019-08-02 | 2020-07-31 | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220257758A1 (https=) |
| EP (1) | EP4007606A4 (https=) |
| JP (1) | JP2022542472A (https=) |
| KR (1) | KR20220044203A (https=) |
| CN (1) | CN114466664A (https=) |
| AU (1) | AU2020325097A1 (https=) |
| BR (1) | BR112022001395A2 (https=) |
| CA (1) | CA3149484A1 (https=) |
| IL (1) | IL290111A (https=) |
| MX (1) | MX2022001403A (https=) |
| WO (1) | WO2021026021A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270304B2 (en) * | 2017-05-05 | 2024-07-01 | Allakos Inc | Methods and preparations for the treatment of inflammatory disorders in the digestive system |
| WO2021081411A1 (en) * | 2019-10-24 | 2021-04-29 | Allakos Inc. | Methods and compositions for treating irritable bowel syndrome and functional dyspepsia |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| WO2024043940A1 (en) * | 2022-08-25 | 2024-02-29 | Allakos Inc. | Methods and compositions for treating atopic dermatitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ720769A (en) * | 2013-12-09 | 2022-10-28 | Allakos Inc | Anti-siglec-8 antibodies and methods of use thereof |
| JP2020504135A (ja) * | 2017-01-06 | 2020-02-06 | アラコス インコーポレイテッド | 慢性閉塞性肺障害を処置するための方法および組成物 |
| EP3618868A4 (en) * | 2017-05-05 | 2021-02-24 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES |
| IL270304B2 (en) * | 2017-05-05 | 2024-07-01 | Allakos Inc | Methods and preparations for the treatment of inflammatory disorders in the digestive system |
-
2020
- 2020-07-31 KR KR1020227006136A patent/KR20220044203A/ko not_active Ceased
- 2020-07-31 US US17/630,474 patent/US20220257758A1/en active Pending
- 2020-07-31 CA CA3149484A patent/CA3149484A1/en active Pending
- 2020-07-31 WO PCT/US2020/044583 patent/WO2021026021A1/en not_active Ceased
- 2020-07-31 CN CN202080067793.2A patent/CN114466664A/zh active Pending
- 2020-07-31 BR BR112022001395A patent/BR112022001395A2/pt not_active IP Right Cessation
- 2020-07-31 MX MX2022001403A patent/MX2022001403A/es unknown
- 2020-07-31 JP JP2022506612A patent/JP2022542472A/ja active Pending
- 2020-07-31 AU AU2020325097A patent/AU2020325097A1/en not_active Abandoned
- 2020-07-31 EP EP20849085.4A patent/EP4007606A4/en not_active Withdrawn
-
2022
- 2022-01-25 IL IL290111A patent/IL290111A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3149484A1 (en) | 2021-02-11 |
| EP4007606A4 (en) | 2023-09-27 |
| KR20220044203A (ko) | 2022-04-06 |
| AU2020325097A1 (en) | 2022-03-03 |
| BR112022001395A2 (pt) | 2022-06-07 |
| CN114466664A (zh) | 2022-05-10 |
| JP2022542472A (ja) | 2022-10-03 |
| IL290111A (en) | 2022-03-01 |
| WO2021026021A1 (en) | 2021-02-11 |
| EP4007606A1 (en) | 2022-06-08 |
| US20220257758A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| Schroeder et al. | The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| MY199655A (en) | Dll3-cd3 bispecific antibodies | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| JP2016509009A5 (https=) | ||
| MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
| JP2023055904A5 (https=) | ||
| SA523440623B1 (ar) | أجسام مضادة | |
| MY210125A (en) | Antibodies binding to b7h4 | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| WO2021087368A3 (en) | Anti-cd45 antibodies and conjugates thereof | |
| JP2020502198A5 (https=) | ||
| MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
| MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
| MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| MX2024012567A (es) | Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| WO2020226986A3 (en) | Methods of treating cancer with an anti-pd-l1 antibody | |
| MX2021001221A (es) | Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3. | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| MX2022006071A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. | |
| MY200701A (en) | Method of averting opioid addiction |